Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oxford Nanopore Technologies plc (ONT.L)
Oxford, GB
Oxford Nanopore Technologies plc, founded in 2005 and originally known as Oxford NanoLabs Limited before its name change in May 2008, is a United Kingdom-based enterprise that specializes in developing and commercializing an innovative system for analyzing diverse molecular structures through nanopore-based sensing. Its product range features a variety of devices, including the portable MinION for sequencing deoxyribonucleic acid and ribonucleic acid, and the MinION Mk1C, which integrates basecalling, data analysis, touchscreen controls, and wireless connectivity. For benchtop operations, the company offers the GridION, capable of running and analyzing up to five MinION or Flongle flow cells, as well as the GridION Mk1 nanopore sequencer. High-yield sequencing is made accessible with the PromethION 2 Solo and PromethION 2, while the PromethION 24 and PromethION 48 provide benchtop nanopore sequencers for multiple users to achieve multi-sample and multi-experiment results. Further complementing these devices are Flongle, an adapter for MinION or GridION units, and VolTRAX, a USB-powered tool designed to automate laboratory processes preceding nanopore sequencing. The company also provides a suite of software solutions: MinKNOW facilitates data acquisition, real-time analysis and feedback, local basecalling, and data streaming; specialized Basecalling tools pinpoint the identity and sequence of bases on DNA/RNA molecules; EPI2ME is a cloud-based platform for comprehensive, real-time analysis of nanopore data; and EPI2ME Labs offers bioinformatics support to help users refine their skills and confidence in analyzing their sequencing data. Additionally, Oxford Nanopore Technologies is actively developing new products such as MinION Mk1D, Ubi, Plongle, and SmidgION. All of its products are available for purchase online.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.63% | +7.43% | +27.40% | +7.59% | +1.63% | +11.53% | +17.86% | -47.00% | -76.62% | -76.62% | -76.62% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 5 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+22.2% ★ Q4'25: +104.5% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+6.3% Q4'25: -10.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-51.4% Q4'25: -11.5% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-69.4% Q4'25: -69.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-62.2% Q4'25: -190.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+7.0% Q4'25: +16.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.39× Q4'25: -0.14× (vs Q4'23)
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 9 EPS Ana. |
Dec 2027 11 Rev. Ana. 9 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
133.66M
est: 124.99M (+6.9%)
|
198.60M
est: 199.02M (-0.2%)
|
169.67M
est: 167.75M (+1.1%)
|
183.19M
est: 184.26M (-0.6%)
|
223.90M
est: 222.53M (+0.6%)
|
274.13M
257.22M – 292.16M
+23.2% YoY
|
339.45M
290.17M – 388.28M
+23.8% YoY
|
415.74M
413.83M – 417.66M
+22.5% YoY
|
496.57M
442.87M – 550.78M
+19.4% YoY
|
602.40M
537.26M – 668.17M
+21.3% YoY
|
| EBITDA |
-140.34M
est: -71.62M (-96.0%)
|
-49.67M
est: -114.04M (+56.4%)
|
-105.71M
est: -95.70M (-10.5%)
|
-93.09M
est: -105.12M (+11.4%)
|
-105.50M
est: -126.95M (+16.9%)
|
-156.39M
-166.68M – -146.74M
-23.2% YoY
|
-193.66M
-221.52M – -165.54M
-23.8% YoY
|
-237.18M
-238.28M – -236.09M
-22.5% YoY
|
-283.29M
-314.22M – -252.66M
-19.4% YoY
|
-343.67M
-381.19M – -306.51M
-21.3% YoY
|
| EBIT |
-165.10M
est: -91.47M (-80.5%)
|
-81.78M
est: -145.66M (+43.9%)
|
-147.56M
est: -124.70M (-18.3%)
|
-136.40M
est: -136.98M (+0.4%)
|
-155.30M
est: -165.43M (+6.1%)
|
-203.79M
-217.19M – -191.22M
-23.2% YoY
|
-252.35M
-288.65M – -215.71M
-23.8% YoY
|
-309.07M
-310.49M – -307.64M
-22.5% YoY
|
-369.15M
-409.46M – -329.23M
-19.4% YoY
|
-447.83M
-496.72M – -399.40M
-21.3% YoY
|
| Net Income |
-167.61M
est: -113.80M (-47.3%)
|
-91.03M
est: -90.54M (-0.5%)
|
-154.51M
est: -159.06M (+2.9%)
|
-146.19M
est: -170.34M (+14.2%)
|
-145.20M
est: -145.20M (+0.0%)
|
-111.04M
-134.25M – -94.92M
+23.5% YoY
|
-75.87M
-110.44M – -51.69M
+31.7% YoY
|
-19.74M
-22.52M – -16.95M
+74.0% YoY
|
13.78M
11.84M – 15.74M
+169.8% YoY
|
48.05M
41.30M – 54.87M
+248.7% YoY
|
| SGA |
161.75M
est: 110.28M (+46.7%)
|
157.45M
est: 175.61M (-10.3%)
|
155.25M
est: 155.29M (0.0%)
|
158.81M
est: 170.57M (-6.9%)
|
188.90M
est: 205.99M (-8.3%)
|
253.77M
238.11M – 270.45M
+23.2% YoY
|
314.23M
268.61M – 359.43M
+23.8% YoY
|
384.85M
383.08M – 386.63M
+22.5% YoY
|
459.67M
409.97M – 509.86M
+19.4% YoY
|
557.64M
497.35M – 618.53M
+21.3% YoY
|
| EPS |
-0.20
est: -0.13 (-57.8%)
|
-0.11
est: -0.10 (-7.2%)
|
-0.19
est: -0.19 (-1.7%)
|
-0.16
est: -0.18 (+9.7%)
|
-0.15
est: -0.14 (-5.1%)
|
-0.11
-0.14 – -0.10
+20.5% YoY
|
-0.08
-0.11 – -0.05
+28.6% YoY
|
-0.02
-0.02 – -0.02
+74.7% YoY
|
0.01
0.01 – 0.02
+169.9% YoY
|
0.05
0.04 – 0.06
+248.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi MSCI UK IMI SRI Climate Paris Aligned UCITS ETF DR - GBP (C) FT1K.L | 1.88% | 3.66M | 0.18% |
| 2 | Amundi MSCI UK IMI SRI Climate Paris Aligned UCITS ETF DR - EUR (C) C1U.PA | 1.88% | 3.66M | 0.18% |
| 3 | WisdomTree BioRevolution UCITS ETF - USD Acc WDNA.L | 0.38% | 85.9K | 0.45% |
| 4 | Amundi Prime UK Mid & Small Cap UCITS ETF DR - GBP (D) PRUK.L | 0.27% | 1.15M | 0.05% |
| 5 | Vanguard FTSE 250 UCITS ETF (GBP) Distributing VMID.DE | 0.21% | 5.49M | 0.10% |
| 6 | Vanguard FTSE 250 UCITS ETF VMIG.MI | 0.21% | 5.49M | 0.10% |
| 7 | Xtrackers FTSE 250 UCITS ETF 1D XMCX.L | 0.18% | 67.5K | 0.15% |
| 8 | Invesco FTSE 250 UCITS ETF S250.L | 0.17% | 60.8K | 0.12% |
| 9 | iShares FTSE 250 UCITS ETF MIDD.L | 0.17% | 1.43M | 0.40% |
| 10 | HSBC FTSE 250 UCITS ETF HMCX.L | 0.16% | 110.6K | 0.09% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gurdial Singh Sanghera | Advisor | 2M | — |
| Nicholas Keher | Chief Financial Officer & Director | 905.6K | male |
| Timothy Cowper | Chief Operating Officer | 422.8K | male |
| Jordan Herman | Senior Vice President & General Counsel | — | male |
| Kathleen Barnes | Senior Vice President of Population Health & Precision Medicine | — | female |
| Lakmal Jayasinghe | Chief Scientific Officer | — | male |
| Richard Compton | Senior Vice President of Sales & Commercial Operations | — | male |
| Sarah Lapworth | Senior Vice President of Global Human Resources | — | female |
| Francis Albert Luc Van Parys | CEO & Executive Director | — | male |
| Zoe McDougall | Senior VP of Strategic Communications & Corporate Affairs | — | female |
| Hagan Bayley | Co-Founder & Member of Technical Advisory Board | — | — |
| John Schoellerman | Senior Vice President of Corporate & Business Development | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ONT.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
